EGFR Exon 20 Mutation: Clinical Trials

2 terminated, 1 active not recruiting. 2 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Active not recruiting 1, Terminated 1
Phase 2	2	Active not recruiting 1, Terminated 1

Follow EGFR Exon 20 Mutation: new trials by email Literature Review of EGFR Exon 20 Mutation trials Research Report on EGFR Exon 20 Mutation

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations BLU-451, Carboplatin, Pemetrexed - Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung	Phase 1	Terminated	Blueprint Medicines Corporation	103	2022-03-04	2025-02-10
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer CLN-081 - Non Small Cell Lung Cancer, EGFR Exon 20 Mutation	Phase 1 / Phase 2	Active not recruiting	Cullinan Therapeutics Inc.	284	2019-10-31	2026-06-17
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Poziotinib - EGFR Exon 20 Mutation, ERBB2 Gene Mutation	Phase 2	Terminated	M.D. Anderson Cancer Center	93	2017-03-17	2026-02-20

Narrower conditions

Carcinoma, Non-Small-Cell Lung (3)  ·  Adenocarcinoma (1)  ·  Brain Neoplasms (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Bronchogenic (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)  ·  Thoracic Neoplasms (1)

Broader conditions

Bronchial Neoplasms (2)  ·  Carcinoma, Bronchogenic (2)  ·  Lung Diseases (2)  ·  Lung Neoplasms (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Respiratory Tract Diseases (2)  ·  Respiratory Tract Neoplasms (2)  ·  Thoracic Neoplasms (2)  ·  Brain Diseases (1)  ·  Bronchial Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Central Nervous System Neoplasms (1)  ·  Neoplasms, Glandular and Epithelial (1)  ·  Nervous System Diseases (1)

Interventions

Carboplatin (1)  ·  HM781-36B (1)  ·  Pemetrexed (1)  ·  zipalertinib (1)

Sponsors

Blueprint Medicines Corporation (1)  ·  Cullinan Therapeutics Inc. (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (3)  ·  Japan (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Canada (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Singapore (1)  ·  Spain (1)

Top investigators

Yasir Y Elamin (1)  ·  Zosia Piotrowska, MD (1)

Results publications

PMID 33122578, PMID 34550757, PMID 35820397, PMID 37384848, PMID 40450572, PMID 40782807